SynergenX is in an early, contested cash-collateral phase, with a July 21 final hearing now focused on whether the debtor can continue using encumbered liquidity while the parties litigate adequate protection and enterprise value. The senior secured lenders have asked to move that hearing until after August 10, arguing that they need more time to test the debtor’s valuation evidence, while offering to extend interim authority on existing terms with an updated budget; SynergenX opposes any delay and says it is prepared to proceed on July 21, as set out in the competing lenders’ continuance motionDkt. 87 and debtor objectionDkt. 90.
The healthcare platform filed Chapter 11 on July 2, 2026, without a prepackaged plan, through its voluntary petitionDkt. 1. SynergenX entered bankruptcy with approximately $82.3 million of funded debt—about $67.6 million under its senior credit agreement and $14.7 million of subordinated notes. In its First Day DeclarationDkt. 9, management attributed the filing to a prolonged default and an escalating dispute with the senior lenders, alleging that lender control impeded refinancing and sale efforts, constrained management and payment decisions, and contributed to losses from a pharmacy venture.
The debtor’s immediate path is operational stabilization rather than a disclosed plan or sale process. Its cash-collateral motionDkt. 13 sought authority to operate under a budget with a 15% variance while granting replacement liens and other adequate protection, but reserved challenges to the validity and perfection of the prepetition liens. SynergenX is also seeking up to $1.5 million to pay additional critical vendors, principally advertising, shipping, and technology providers, through its . The July 21 hearing—or the court’s disposition of the requested continuance—is the near-term gating event for liquidity and will determine whether the case remains on interim terms while the valuation dispute develops.
